May & Baker Nigeria plc (NGX:MAYBAKER)

Market Cap	80.57B +424.7%
Revenue (ttm)	37.16B +16.2%
Net Income	4.57B +116.3%
EPS	2.65 +116.3%
Shares Out	1.73B
PE Ratio	17.64
Forward PE	n/a
Dividend	0.40 (0.86%)
Ex-Dividend Date	May 20, 2026

Volume	1,005,496
Open	n/a
Previous Close	46.70
Day's Range	n/a
52-Week Range	10.90 - 52.50
Beta	0.49
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 28, 2026

About May & Baker Nigeria

May & Baker Nigeria Plc, together with its subsidiaries, manufactures, sells, and distributes human pharmaceuticals, human vaccines, and consumer products in Nigeria. It operates through Pharmaceuticals and Beverage segments. The company offers pharmaceuticals, including anti-diabetic, anti-hypersensitive, anti-infective, anti-malaria, analgesic, cough and cold, and anxiolytics; and nature care products. It also provides beverage drinks, including bottled water under the Lily Water name; and hand and surface sanitizers under the Smartans name. ...

• Industry: Pharmaceutical Preparations
• Founded: 1944
• Employees: 397
• Stock Exchange: Nigerian Stock Exchange
• Ticker Symbol: MAYBAKER

Financial Performance

In 2025, May & Baker Nigeria's revenue was 38.26 billion, an increase of 32.38% compared to the previous year's 28.91 billion. Earnings were 4.44 billion, an increase of 173.70%.